Lido Advisors LLC increased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 10.8% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,078 shares of the life sciences company’s stock after purchasing an additional 203 shares during the period. Lido Advisors LLC’s holdings in Illumina were worth $762,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Moneta Group Investment Advisors LLC lifted its position in Illumina by 2,670.0% during the second quarter. Moneta Group Investment Advisors LLC now owns 9,695 shares of the life sciences company’s stock valued at $107,000 after acquiring an additional 9,345 shares during the last quarter. Sun Life Financial INC lifted its position in Illumina by 152.5% during the second quarter. Sun Life Financial INC now owns 399 shares of the life sciences company’s stock valued at $111,000 after acquiring an additional 241 shares during the last quarter. Highstreet Asset Management Inc. purchased a new stake in Illumina during the third quarter valued at approximately $112,000. Migdal Insurance & Financial Holdings Ltd. lifted its position in Illumina by 3,192.3% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 428 shares of the life sciences company’s stock valued at $120,000 after acquiring an additional 415 shares during the last quarter. Finally, Ancora Advisors LLC purchased a new stake in Illumina during the third quarter valued at approximately $145,000. Hedge funds and other institutional investors own 88.91% of the company’s stock.

NASDAQ ILMN opened at $321.41 on Friday. The firm has a market capitalization of $49.15 billion, a price-to-earnings ratio of 57.25, a P/E/G ratio of 2.48 and a beta of 1.09. Illumina, Inc. has a 12-month low of $207.51 and a 12-month high of $372.61. The company has a debt-to-equity ratio of 0.24, a current ratio of 2.46 and a quick ratio of 2.24.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Tuesday, October 23rd. The life sciences company reported $1.52 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.26 by $0.26. The business had revenue of $853.00 million during the quarter, compared to analysts’ expectations of $825.65 million. Illumina had a net margin of 21.09% and a return on equity of 27.10%. The business’s quarterly revenue was up 19.5% on a year-over-year basis. During the same quarter last year, the company posted $1.11 earnings per share. As a group, equities analysts anticipate that Illumina, Inc. will post 5.75 earnings per share for the current year.

In other Illumina news, EVP Marc Stapley sold 1,000 shares of the firm’s stock in a transaction on Thursday, December 6th. The shares were sold at an average price of $329.69, for a total value of $329,690.00. Following the completion of the transaction, the executive vice president now owns 7,857 shares of the company’s stock, valued at $2,590,374.33. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Robert S. Epstein sold 1,346 shares of the firm’s stock in a transaction on Monday, October 1st. The stock was sold at an average price of $369.15, for a total transaction of $496,875.90. The disclosure for this sale can be found here. In the last ninety days, insiders sold 71,082 shares of company stock valued at $23,398,609. Corporate insiders own 0.54% of the company’s stock.

A number of equities research analysts recently commented on the stock. Zacks Investment Research cut shares of Illumina from a “buy” rating to a “hold” rating in a research report on Wednesday, October 24th. Barclays increased their target price on shares of Illumina from $350.00 to $370.00 and gave the company an “overweight” rating in a research report on Wednesday, October 24th. BidaskClub cut shares of Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, October 16th. Deutsche Bank increased their target price on shares of Illumina to $350.00 and gave the company a “buy” rating in a research report on Friday, October 12th. Finally, ValuEngine cut shares of Illumina from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 11th. Six analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Illumina currently has a consensus rating of “Buy” and a consensus price target of $330.94.

COPYRIGHT VIOLATION WARNING: This story was first reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.watchlistnews.com/lido-advisors-llc-acquires-203-shares-of-illumina-inc-ilmn/2669758.html.

About Illumina

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Further Reading: What is a conference call?

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.